Information Provided By: 
Fly News Breaks for February 6, 2019
NBIX
Feb 6, 2019 | 07:34 EDT
Cantor Fitzgerald analyst Charles Duncan raised his price target for Neurocrine Biosciences to $127 and reiterates an Overweight rating on the shares. The company reported Q4 revenue of $131.5M and cash of $867M, which is more than sufficient to fund its pipeline and commercial effort into 2021, Duncan tells investors in a post-earnings research note. The analyst remains convinced that Ingrezza sales will continue to grow in 2019 and beyond.
News For NBIX From the Last 2 Days
